H.C. Wainwright analyst Brandon Folkes initiated coverage of Journey Medical (DERM) with a Buy rating and $13 price target The firm believes the company’s Emrosi has demonstrated clinical superiority to market leader Oracea in rosacea. This creates the potential for prescription demand and revenue pull through to exceed current consensus expectations, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: